MoneyWorks4Me

Bacil Pharma - Quaterly Results

13 Feb 2024 Evaluate
Revenue showed a marginal decline at Rs. 0.00 millions. For the quarter ended December 2023, as compared to corresponding quarter of last year.The Net Loss for the quarter ended December 2023 is Rs. -0.24 millions as compared to Net Loss of Rs. -0.45 millions of corresponding quarter ended December 2022 Operating profit Margin for the quarter ended December 2023 improved to -0.23% as compared to -0.44% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income 0.33 0.02 1550.00 1.10 1.06 3.77 1.15 0.58 98.28
PBIDT -0.23 -0.44 -47.73 -0.16 -0.25 -36.00 -0.99 -38.56 -97.43
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT -0.23 -0.44 -47.73 -0.16 -0.25 -36.00 -0.99 -38.56 -97.43
Depreciation 0.01 0.01 0.00 0.03 0.03 0.00 0.03 0.04 -25.00
PBT -0.24 -0.45 -46.67 -0.19 -0.28 -32.14 -1.02 -38.60 -97.36
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -0.24 -0.45 -46.67 -0.19 -0.28 -32.14 -1.02 -38.60 -97.36
Equity 58.90 58.90 0.00 58.90 58.90 0.00 58.90 58.90 0.00
PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..